Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Targeted therapy for EWS-FLI1 in ewing sarcoma.
Cancers 15:21 (2023)
Ewing sarcoma (EwS) is a rare and predominantly pediatric malignancy of bone and soft tissue in children and adolescents. Although international collaborations have greatly improved the prognosis of most EwS, the occurrence of macrometastases or relapse remains challenging. The prototypic oncogene EWS-FLI1 acts as an aberrant transcription factor that drives the cellular transformation of EwS. In addition to its involvement in RNA splicing and the DNA damage response, this chimeric protein directly binds to GGAA repeats, thereby modifying the transcriptional profile of EwS. Direct pharmacological targeting of EWS-FLI1 is difficult because of its intrinsically disordered structure. However, targeting the EWS-FLI1 protein complex or downstream pathways provides additional therapeutic options. This review describes the EWS-FLI1 protein partners and downstream pathways, as well as the related target therapies for the treatment of EwS.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Altmetric
5.200
0.000
1
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Ews-fli1 ; Ewing Sarcoma ; Immunotherapy ; Protein Complex ; Targeted Therapy; 6-transmembrane Epithelial Antigen; Direct Transcriptional Target; Fusion Protein; Tumor-growth; In-vitro; T-cells; Histone Deacetylase; Ewsr1-fli1 Activity; Genomic Landscape; Binding Protein
Language
english
Publication Year
2023
HGF-reported in Year
2023
ISSN (print) / ISBN
2072-6694
Journal
Cancers
Quellenangaben
Volume: 15,
Issue: 16,
Article Number: 21
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-554300-001
Grants
China Scholarship Council
WOS ID
001169053300101
WOS ID
001055792300001
Scopus ID
85169033789
PubMed ID
37627063
Erfassungsdatum
2023-10-06